The situation remains critical in the country with the sudden spike in cases during the second wave. While it’s every persons wish now to get vaccinated but the supply of vaccines are limited and it may be more prudent to reset the vaccination plan to
Strengthens offerings & continues to be at the forefront of COVID care Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems
Study shows that 97.38% of those vaccinated were protected from an infection and hospitalization rate was only 0.06% with mainly minor infections that do not lead to severe disease or hospitalization Hospital urges citizens to resist vaccine hesitancy to tide over the pandemic Indraprastha
